---
title: "中国生物制药称，国家药品监督管理局已批准 Benmelstobart 注射液上市"
description: "中国生物制药表示，国家药品监督管理局已批准 Benmelstobart 注射剂上市"
type: "news"
locale: "zh-CN"
url: "https://longbridge.com/zh-CN/news/276024005.md"
published_at: "2026-02-16T02:05:56.000Z"
---

# 中国生物制药称，国家药品监督管理局已批准 Benmelstobart 注射液上市

> 中国生物制药表示，国家药品监督管理局已批准 Benmelstobart 注射剂上市

### Related Stocks

- [516820.CN - 平安中证医疗创新ETF](https://longbridge.com/zh-CN/quote/516820.CN.md)
- [159102.CN - 华安恒生生物科技ETF](https://longbridge.com/zh-CN/quote/159102.CN.md)
- [589720.CN - 国泰上证科创板创新药ETF](https://longbridge.com/zh-CN/quote/589720.CN.md)
- [516500.CN - 华夏中证生物科技主题ETF](https://longbridge.com/zh-CN/quote/516500.CN.md)
- [01177.HK - 中国生物制药](https://longbridge.com/zh-CN/quote/01177.HK.md)
- [159929.CN - 汇添富中证医药卫生ETF](https://longbridge.com/zh-CN/quote/159929.CN.md)
- [159837.CN - 易方达中证生物科技主题ETF](https://longbridge.com/zh-CN/quote/159837.CN.md)
- [512290.CN - 国泰中证生物医药ETF](https://longbridge.com/zh-CN/quote/512290.CN.md)
- [588250.CN - 鹏华上证科创板生物医药ETF](https://longbridge.com/zh-CN/quote/588250.CN.md)
- [560600.CN - 方正富邦中证医药及医疗器械创新ETF](https://longbridge.com/zh-CN/quote/560600.CN.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Sino Biopharmaceutical Completes Subject Enrollment in Phase 3 Trial of Breast Cancer Drug | Sino Biopharmaceutical Completes Subject Enrollment in Phase 3 Trial of Breast Cancer Drug | [Link](https://longbridge.com/zh-CN/news/275387692.md) |
| Sino Biopharm Wins China Nod for New Lung Cancer Use of PD-L1 Drug | Sino Biopharmaceutical has received Chinese regulatory approval for its PD-L1 inhibitor, benmelstobart, for use as maint | [Link](https://longbridge.com/zh-CN/news/276016059.md) |
| Shanghai Henlius Biotech Doses First Patient in Phase 1b/2 Trial of HLX43 Combination for Advanced Colorectal Cancer | Shanghai Henlius Biotech Inc. has initiated a phase 1b/2 clinical trial for HLX43, an anti-PD-L1 antibody-drug conjugate | [Link](https://longbridge.com/zh-CN/news/275577160.md) |
| Nanjing Leads Biolabs Doses First Patient in Phase Ib/II Trial of Opamtistomig for Metastatic Triple-Negative Breast Cancer | Nanjing Leads Biolabs Co., Ltd. has initiated a Phase Ib/II clinical trial for its drug Opamtistomig, targeting recurren | [Link](https://longbridge.com/zh-CN/news/275425267.md) |
| WuXi XDC Launches Cash Offer to Acquire All Remaining Shares of BioDlink | WuXi XDC Cayman Inc. has launched a voluntary conditional cash offer to acquire all remaining shares of BioDlink not alr | [Link](https://longbridge.com/zh-CN/news/275670240.md) |

---

> **免责声明**：本文内容仅供参考，不构成任何投资建议。